search
Back to results

Assessment of Injectable Medication Platforms

Primary Purpose

Overdose Antidote, Bleeding, Allergic Reaction

Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Autoinjector
Standard Injector
Prefilled
Sponsored by
Canadian Forces Health Services Centre Ottawa
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Overdose Antidote focused on measuring autoinjector, needle, syringe, medication

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • any participant over the age of 18 able to provide consent

Exclusion Criteria:

  • only participants with pre specified conditions impacting cognitive and/or manual dexterity will be excluded
  • recent substance use
  • non health care workers injection with experience with medication injection in last 12 months

Sites / Locations

  • Canadian ForcesRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Injection Scenario

Arm Description

For each scenario participants will be asked to administer/inject the "medication" (likely saline or air) using various methods: 1) standard protocol , 2) Autoinjector 3) Pre-filled syringes. For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).

Outcomes

Primary Outcome Measures

Change in medication Injection/delivery time for each trial
Time in seconds will be measured from the start of the scenario and stopped once the medication has been delivered to the orange.

Secondary Outcome Measures

Number of injection failures and/or injuries associated with each trial
Any human errors or device failures will be recorded
Perceived difficulty of injection based on type of system
On a scale of 1-5 participants will rate difficult using autoinjector, prefilled and standard medication delivery systems. Going from 1-5 represents a decreasing degree of difficulty (hardest =5 and easiest = 1 with 3 being neutral)

Full Information

First Posted
April 28, 2022
Last Updated
February 6, 2023
Sponsor
Canadian Forces Health Services Centre Ottawa
search

1. Study Identification

Unique Protocol Identification Number
NCT05367531
Brief Title
Assessment of Injectable Medication Platforms
Official Title
Quantitative Assessment of Injectable Medication Delivery Practices
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 30, 2022 (Actual)
Primary Completion Date
December 1, 2024 (Anticipated)
Study Completion Date
January 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Canadian Forces Health Services Centre Ottawa

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Background: While medical advances for in-hospital care rapidly evolve, a mainstay of effective pre-hospital care remains the ability to treat medical emergencies such as anaphylaxis, prolonged seizure, overdose, or uncontrolled bleeding, through rapid administration of appropriate medication. Autoinjectors are used globally to deliver medications in a timely manner, often in environments where immediate access to medical facilities is limited. Rapid administration of intramuscular medication delivery is essential where oral or intravenous delivery is either not possible or ineffective. The purpose of the proposed study seeks to determine the efficiency various types of medication injection administration.
Detailed Description
Research Objective: To understand the efficiency of injectable medication delivery in the Canadian Forces and civilian world for improved care delivery in military and pre-hospital environments. Participants: Approximately thirty (30) participants will be recruited for the study. Methods: Data will be obtained on the technical comparison of efficiency for pre-filled syringes to the current standards of administration. The timing and accuracy for administering saline to an inanimate object using the traditional methods versus a pre-filled medication syringes will be compared. Risks and Risk Mitigation: The participants in this study are all practicing military personnel who are able to give free and informed consent. To reduce undue influence, LCol Meredith and Dr Gupta will not be involved in recruitment. As a result, these participants are a low vulnerability group. The risk of any adverse events is low since data scenarios, and participants may choose to skip any questions or scenarios that participants do not wish to do. Investigators will remind all participants that their participation is voluntary, and that they may choose to withdraw or stop at any time. Benefits and Military Significance: The proposed study will be the first of its kind to assess the efficiency of various injectable medication delivery platforms. This data will provide a background for improving injectable drug delivery practices in various setting (eg military and pre-hospital settings), including the potential to inform novel medical device development.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overdose Antidote, Bleeding, Allergic Reaction
Keywords
autoinjector, needle, syringe, medication

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
For each scenario participants will be asked to administer/inject the "medication" (likely saline or air) using various methods: 1) standard protocol , 2) Autoinjector 3) Pre-filled syringes. For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).
Masking
None (Open Label)
Masking Description
The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience).
Allocation
N/A
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Injection Scenario
Arm Type
Experimental
Arm Description
For each scenario participants will be asked to administer/inject the "medication" (likely saline or air) using various methods: 1) standard protocol , 2) Autoinjector 3) Pre-filled syringes. For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).
Intervention Type
Device
Intervention Name(s)
Autoinjector
Intervention Description
For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding). The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience).
Intervention Type
Device
Intervention Name(s)
Standard Injector
Intervention Description
For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding). The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience).
Intervention Type
Device
Intervention Name(s)
Prefilled
Intervention Description
For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding). The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience).
Primary Outcome Measure Information:
Title
Change in medication Injection/delivery time for each trial
Description
Time in seconds will be measured from the start of the scenario and stopped once the medication has been delivered to the orange.
Time Frame
immediately after intervention
Secondary Outcome Measure Information:
Title
Number of injection failures and/or injuries associated with each trial
Description
Any human errors or device failures will be recorded
Time Frame
immediately after intervention
Title
Perceived difficulty of injection based on type of system
Description
On a scale of 1-5 participants will rate difficult using autoinjector, prefilled and standard medication delivery systems. Going from 1-5 represents a decreasing degree of difficulty (hardest =5 and easiest = 1 with 3 being neutral)
Time Frame
immediately after intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: any participant over the age of 18 able to provide consent Exclusion Criteria: only participants with pre specified conditions impacting cognitive and/or manual dexterity will be excluded recent substance use non health care workers injection with experience with medication injection in last 12 months
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Gaurav Gupta, MD
Phone
6139451601
Email
gaurav.gupta@forces.gc.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Sean Meredith, PharmD
Phone
6139451601
Email
SEAN.MEREDITH@forces.gc.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gaurav Gupta, MD
Organizational Affiliation
CAF
Official's Role
Principal Investigator
Facility Information:
Facility Name
Canadian Forces
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1K 0T2
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gaurav Gupta, MD
Phone
6139451601
Email
gaurav.gupta@forces.gc.ca

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Assessment of Injectable Medication Platforms

We'll reach out to this number within 24 hrs